Shop

When on the hunt for a job, make sure your LinkedIn profile is just as polished and updated as your resume. If you aren’t getting responses from recruiters, chances are your profile is missing pertinent keywords that bots aren’t selecting. In addition, dress codes have changed too, so you’ll need to know new technologies such as Slack and Google+ Hangouts. If you have no idea what any of this means, YOU’RE NOT ALONE.

You’re one of the forty-five percent of women who, after taking a career break, quickly discovered that the job search has changed rapidly in the last decade. With new modes of communication, rules of discoverability and expectations, this book lays out a clear path for anyone ready to re-enter the workforce.

Getting started is much easier when you know what the first step should be. In Back to Business, career coaching and re-entry experts Nancy McSharry Jensen and Sarah Duenwald, have put together a guide for women returning to the workplace.

Practical and easy to understand, Back to Business teaches you how to:

-Identify and talk about what you want.
-Understand your personal brand and how your skills translate to your new career.
-Become professionally relevant and gain confidence in returning to the workforce.
-Look for job opportunities while being productive and intentional with your time.

Nancy and Sarah understand through first-hand experience the anxiety of returning to work. They have helped hundreds of women facing the job search process to overcome the anxiety of what is often overwhelming life change.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.